Long-term Persistence of Hepatitis A Antibodies in Healthy Adults, Primed 21 to 25 Years Earlier With GSK Biologicals' Hepatitis A Vaccine Havrix (SB208109) in Studies HAV-112 (208109/108) or HAV-123 (208109/114)
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2015
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 17 Nov 2015 Status changed from Not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 15 Aug 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 11 Aug 2014 New source identified and integrated (European Clinical Trials Database record:EudraCT2013-001918-15 ).